Literature DB >> 23414472

Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

David R Raleigh1, Daphne A Haas-Kogan.   

Abstract

The cellular reaction to genomic instability includes a network of signal transduction pathways collectively referred to as the DNA damage response (DDR). Activated by a variety of DNA lesions, the DDR orchestrates cell cycle arrest and DNA repair, and initiates apoptosis in instances where damage cannot be repaired. As such, disruption of the DDR increases the prevalence of DNA damage secondary to incomplete repair, and in doing so, enhances radiation-induced cytotoxicity. This article describes the molecular agents and their targets within DDR pathways that sensitize cells to radiation. Moreover, it reviews the therapeutic implications of these compounds, provides an overview of relevant clinical trials and offers a viewpoint on the evolution of the field in the years to come.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23414472      PMCID: PMC3635474          DOI: 10.2217/fon.12.185

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  153 in total

1.  A possible mechanism for hyperthermic radiosensitization mediated through hyperthermic lability of Ku subunits in DNA-dependent protein kinase.

Authors:  Y Matsumoto; N Suzuki; K Sakai; A Morimatsu; K Hirano; H Murofushi
Journal:  Biochem Biophys Res Commun       Date:  1997-05-29       Impact factor: 3.575

2.  DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.

Authors:  E P Rogakou; D R Pilch; A H Orr; V S Ivanova; W M Bonner
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

3.  Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma.

Authors:  G J Wiedemann; H I Robins; S Gutsche; M Mentzel; M Deeken; D M Katschinski; S Eleftheriadis; R Crahé; C Weiss; B Storer; T Wagner
Journal:  Eur J Cancer       Date:  1996-05       Impact factor: 9.162

4.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

Authors:  Q Wang; S Fan; A Eastman; P J Worland; E A Sausville; P M O'Connor
Journal:  J Natl Cancer Inst       Date:  1996-07-17       Impact factor: 13.506

Review 5.  The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy.

Authors:  R G Bristow; S Benchimol; R P Hill
Journal:  Radiother Oncol       Date:  1996-09       Impact factor: 6.280

Review 6.  p53 and ATM: cell cycle, cell death, and cancer.

Authors:  S E Morgan; M B Kastan
Journal:  Adv Cancer Res       Date:  1997       Impact factor: 6.242

7.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

8.  Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase.

Authors:  S L Yao; A J Akhtar; K A McKenna; G C Bedi; D Sidransky; M Mabry; R Ravi; M I Collector; R J Jones; S J Sharkis; E J Fuchs; A Bedi
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

9.  The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.

Authors:  B D Price; M B Youmell
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

10.  Atm-deficient mice: a paradigm of ataxia telangiectasia.

Authors:  C Barlow; S Hirotsune; R Paylor; M Liyanage; M Eckhaus; F Collins; Y Shiloh; J N Crawley; T Ried; D Tagle; A Wynshaw-Boris
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

View more
  27 in total

1.  Integr(at)in(g) EGFR therapy in HNSCC.

Authors:  Valentina D'Amato; Roberta Rosa; Roberto Bianco
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Personalized radiotherapy: concepts, biomarkers and trial design.

Authors:  A H Ree; K R Redalen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

Review 3.  Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Authors:  Mohammad K Khan; Tahseen H Nasti; Zachary S Buchwald; Ralph R Weichselbaum; Stephen J Kron
Journal:  Cancer J       Date:  2019 Mar/Apr       Impact factor: 3.360

4.  Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx.

Authors:  Lijun Zhu; Erich M Sturgis; Hua Zhang; Zhongming Lu; Ye Tao; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2017-07-07       Impact factor: 7.396

5.  Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Authors:  Sharmistha Pal; David Kozono; Xiaodong Yang; Wojciech Fendler; Whitney Fitts; Jing Ni; John A Alberta; Jean Zhao; Kevin X Liu; Jie Bian; Nathalene Truffaux; William A Weiss; Adam C Resnick; Pratiti Bandopadhayay; Keith L Ligon; Steven G DuBois; Sabine Mueller; Dipanjan Chowdhury; Daphne A Haas-Kogan
Journal:  Cancer Res       Date:  2018-05-14       Impact factor: 12.701

6.  Enhancement of cellular radiation sensitivity through degradation of Chk1 by the XIAP-XAF1 complex.

Authors:  Kwang Seok Kim; Jong-Ik Heo; Kyu Jin Choi; Sangwoo Bae
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

7.  Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells.

Authors:  Shijie Zhang; Lei Wang; Hongchun Liu; Guoqiang Zhao; Liang Ming
Journal:  Diagn Pathol       Date:  2014-03-20       Impact factor: 2.644

8.  Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

Authors:  Lisa Buckel; Elamprakash N Savariar; Jessica L Crisp; Karra A Jones; Angel M Hicks; Daniel J Scanderbeg; Quyen T Nguyen; Jason K Sicklick; Andrew M Lowy; Roger Y Tsien; Sunil J Advani
Journal:  Cancer Res       Date:  2015-02-13       Impact factor: 12.701

9.  FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma.

Authors:  Zuoquan Zhu; Jiahang Song; Junjie Gu; Bing Xu; Xinchen Sun; Shu Zhang
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

10.  DCLK1 Inhibition Sensitizes Colorectal Cancer Cells to Radiation Treatment.

Authors:  Chiman Mohammadi; Ali Mahdavinezhad; Massoud Saidijam; Fatemeh Bahreini; Abdolazim Sedighi Pashaki; Mohammad Hadi Gholami; Rezvan Najafi
Journal:  Int J Mol Cell Med       Date:  2021-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.